VIVEbiotech achieves significant business growth in 2023 with increases in demand for its lentiviral vector specialization and capabilities
VIVEbiotech today announces significant growth in 2023, with sales increasing by 70%.
- Recent company sales grow by 70%, reflecting expanded capabilities and industry recognition of VIVEbiotech’s expertise in manufacturing lentiviruses, now used in in 70% of global ex-vivo CGT clinical trials
- VIVEbiotech is able to manufacture integrating, and non-integrating, different pseudotypes and generations of lentiviral vectors tailored to meet individual needs, using its well-established plug and play platform
- VIVEbiotech has this year supported the manufacture of seven lentiviruses for in vivo use, with one approved for clinical trials
VIVEbiotech: A Global Leader in GMP Lentiviral Vector Manufacturing for Gene Therapy
The global demand for lentiviral vectors continues to rise, especially in the field of regenerative medicine. As a specialized GMP lentiviral vector CDMO, VIVEbiotech is enabling groundbreaking advancements through the production of safe, scalable, and regulatory-compliant lentiviruses for both in vivo and ex vivo applications.
With lentiviral vectors playing a crucial role in delivering therapeutic genes into specific cell types, including hematopoietic stem cells, the biotech industry increasingly depends on experienced CDMOs to navigate complex processes such as gene delivery, transgene expression, and the modification of host cell genomes.
This article explores the expanding role of lentivirus in vivo, the advantages of GMP-grade viral vector manufacturing, and how VIVEbiotech is positioned as a global leader in this fast-evolving landscape.
Why Lentiviral Vectors Are Essential in Regenerative Medicine
Among the wide array of viral vectors, lentiviruses stand out for their efficiency in integrating therapeutic genes into the host cell genome, allowing long-term expression. Their ability to target both dividing and non-dividing cells makes them especially valuable for treating inborn errors and chronic diseases.
Gene therapy and regenerative medicine rely heavily on such viruses to modify cell types involved in the repair or replacement of damaged tissues. For instance, most chimeric antigen receptor (CAR) T-cell therapies depend on lentiviral vectors to deliver genes that allow immune cells to recognize and kill cancer cells.
The Rise of Lentivirus In Vivo Applications
Lentiviruses are no longer limited to ex vivo approaches. The use of lentivirus in vivo—where vectors are delivered directly into the body—is gaining momentum thanks to enhanced safety profiles and vector engineering advancements.
In 2023, VIVEbiotech supported the development of seven lentiviral vectors for in vivo use, with one gaining approval for clinical trials. This is a major step forward in making therapies more accessible and efficient, avoiding the need to manipulate cells outside the patient’s body.
These retroviruses are especially effective in targeting host cells with high specificity, thanks to the evolution of receptor-targeting pseudotypes that can be tailored for different cell lines and tissues.
Scalable and Regulatory-Compliant Lentivirus Manufacturing
As a specialized CDMO, VIVEbiotech provides end-to-end support for the production of GMP lentiviruses. The company’s plug-and-play manufacturing platform enables the creation of both integrating and non-integrating vectors across multiple vector generations.
With over 50 reactor batches delivered to more than 45 clients globally, VIVEbiotech ensures consistency, safety, and compliance with both EMA and FDA standards.
Their flexibility supports the unique needs of each client — from small-batch early-stage development to large-scale commercial production — and enables rapid adaptation across several therapeutic areas.
Gene Transfer and Transgene Expression: Keys to Targeted Therapies
Successful gene transfer depends on selecting the appropriate vector and ensuring that it reaches the right host cell and expresses the intended gene correctly. VIVEbiotech’s expertise in lentiviral vector design supports the stable expression of transgenes across diverse applications.
In addition to oncology, these approaches are being applied in rare diseases, metabolic disorders, and immune deficiencies — where precision targeting and long-term expression are essential.
VIVEbiotech’s 2023 Growth Reflects Global Demand
VIVEbiotech’s 70% growth in 2023 reflects the biotechnology industry’s increasing reliance on high-quality, specialized lentiviral vector CDMOs. This growth was supported by new manufacturing capacity, a skilled workforce, and expanded capabilities in lentivirus in vivo production.
Thanks to their deep understanding of viral biology, VIVEbiotech helps partners across Europe, the U.S., Asia, and Australia bring next-generation therapies closer to patients.
Outlook: The Future of Viral Vector Manufacturing
As gene therapies continue to advance, the role of lentiviral vectors will remain central. The unique features of lentiviruses — stable integration, safety, and customizability — ensure they will continue to lead in gene delivery applications.
The ability to produce compliant, efficient, and flexible vectors will be essential.
Read the Full Press Release Below
To learn more about VIVEbiotech’s capabilities, milestones, and commitment to excellence in GMP lentivirus manufacturing, continue reading the official press release below. VIVEbiotech has achieved this growth by further increasing its capabilities, including introducing the ability to manufacture both integrating and non-integrating, different pseudotypes and different generations of LVVs. VIVEbiotech’s clients also reached important clinical milestones, with a number approaching commercial phases. Finally, VIVEbiotech is manufacturing LVVs for a recently-approved clinical trial where the LVVs will be administered in vivo .
VIVEbiotech has achieved this growth by further increasing its capabilities, including introducing the ability to manufacture both integrating and non-integrating, different pseudotypes and different generations of LVVs. VIVEbiotech’s clients also reached important clinical milestones, with a number approaching commercial phases. Finally, VIVEbiotech is manufacturing LVVs for a recently-approved clinical trial where the LVVs will be administered in vivo.
With LVV demand continuing to increase globally, VIVEbiotech’s established reputation as a market leader and expert in virology and lentiviral vector production has continued to attract new partners and, importantly, strengthened relationships with existing customers that are advancing development of their respective therapies. VIVEbiotech now supports 45 international customers with productive, cost-effective and regulatory compliant LVVs.
In 2021, VIVEbiotech expanded manufacturing capacity through the launch of its new facility. The increase in capacity has allowed higher quantities to be manufactured. In addition, the company’s growth in 2023 would not be achievable without ongoing increases in its highly qualified and knowledgeable teams. These capacity and team enhancements allow VIVEbiotech to offer technical adaptation and flexibility while remaining custom-centric.
“With lentiviral vectors used in 70% of ex vivo gene therapy clinical trials, and one-third of all cell and gene therapy clinical trials, the market heavily relies on experienced manufacturers of lentiviral vectors, such as VIVEbiotech, to bring these promising therapies to patients,” said Gurutz Linazasoro, MD, CEO, VIVEbiotech. “This year, VIVEbiotech has experienced a substantial increase in companies using lentiviral vectors for in vivo gene therapies. Reliance on lentiviral vectors will continue to expand through 2024, specifically due to the enhanced safety LVVs offer. As a result of our specialization in the development and manufacture of lentiviral vectors, and our recent increases in both capacity and the specialization of our teams, VIVEbiotech is able to give our clients the quality they need.”
VIVEbiotech operates according to both EMA’s and FDA’s standards. The company has manufactured more than 100 batches in reactors, using its fully developed plug and play platform. VIVEbiotech is able to perform the required optimization from very early stages to develop vectors that meet individual needs of each client and therapy. VIVEbiotech is developing and manufacturing cost-effective, scalable, and regulatory compliant vectors for biotech and pharmaceutical companies in Europe, US, Asia and Australia.
Media Contacts:
IB Communications